NEW YORK (GenomeWeb News) — General Electric late yesterday said it plans to acquire two of Abbott Technologies’ diagnostics businesses for $8.13 billion in cash, and will leave alone the company’s molecular diagnostic unit.
 
The acquisition includes Abbott’s in vitro diagnostics and point-of-care divisions and represents another rung in GE Healthcare’s goal of creating a business that combines in vitro and in vivo technologies to diagnose diseases.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.